Advanced Stage NSCLC
Conditions
Interventions
Sponsors
Teikyo University Hospital
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: Patients with stage III or stage IV non-small cell lung cancer. Patients receiving immune checkpoint inhibitors (ICIs) either as monotherapy or in combination with other treatments. Patients who have undergone 2 to 4 courses of ICI therapy. Patients who have not experienced Grade 3 or higher immune-related adverse events (irAEs) from previous treatments.
Exclusion criteria
Exclusion criteria: Minors (under 18 years old). Patients with a performance status (PS) of 2 or higher. Patients currently using or with a history of using antibiotics or proton pump inhibitors (PPIs). Patients with cachexia. Patients with inflammatory bowel disease. Patients with a history of ileus or at risk of other gastrointestinal passage obstructions. Patients with driver mutations (e.g., EGFR, ALK, ROS-1, BRAF, MET, RET, NTRK, KRAS G12C, HER2). Patients considered unable to provide informed consent independently due to cognitive decline or other reasons. Any other patients deemed unsuitable by the attending physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in the gut microbiota before and after guidance | — |
Countries
Japan
Contacts
Public ContactNobuhiko Seki
Teikyo University Hospital Department of oncology
Outcome results
None listed